$Novavax(N_老虎社区_美港股上老虎

2021-12-10

$Novavax(NVAX)$is not a good choice for pharma. Better to go with $Moderna, Inc.(MRNA)$or $Pfizer(PFE)$

What in the World Is Going on With Novavax Stock?

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":605869638,"tweetId":"605869638","gmtCreate":1639145487293,"gmtModify":1639145539758,"author":{"id":4091678983335410,"idStr":"4091678983335410","authorId":4091678983335410,"authorIdStr":"4091678983335410","name":"MoneyCentral","avatar":"https://static.tigerbbs.com/b65487e9bb510d46c3ac12f7427011cb","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":34,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>is not a good choice for pharma. Better to go with <a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>or <a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a></p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>is not a good choice for pharma. Better to go with <a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>or <a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a></p></body></html>","text":"$Novavax(NVAX)$is not a good choice for pharma. Better to go with $Moderna, Inc.(MRNA)$or $Pfizer(PFE)$","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/605869638","repostId":2190626076,"repostType":4,"repost":{"id":"2190626076","kind":"highlight","pubTimestamp":1639144128,"share":"https://www.laohu8.com/m/news/2190626076?lang=&edition=full","pubTime":"2021-12-10 21:48","market":"us","language":"en","title":"What in the World Is Going on With Novavax Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2190626076","media":"Motley Fool","summary":"It's being simultaneously battered by setbacks and buoyed by optimism.","content":"<p>It's a cliche to say that certain stocks are like roller coaster rides, but the coronavirus vaccine developer <b>Novavax </b>(NASDAQ:NVAX) has given a completely new meaning to the term over the last 12 months. While it's up more than 64% this year, in the last three months shareholders have taken losses of about 27%, which means that many of the people who bought shares at the peak early this year are likely to be displeased.</p>\n<p>Still, in the last month alone, Novavax's stock has climbed sharply as the company scored crucial approvals for its vaccine and started commercialization of its vaccine in international markets like the Philippines and Indonesia. And the omicron variant appears to have juiced it even further.</p>\n<p>But as a result of even more delays with its manufacturing and the filing of a class action lawsuit by shareholders, things are far from settled. Especially for investors who are wondering whether to keep holding Novavax, it's worth investigating what's going on in more detail.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f9c98d1583591447241f9bc0b1534489\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Delays keep piling up</h2>\n<p>It's obvious that investors are eager for Novavax's vaccine to get the global rollout that the company has been working for since the start of the pandemic, but bumps in the road are slowing things up.</p>\n<p>Manufacturing has been a problem since late last year, when the company announced that its all-important phase 3 clinical trials would need to be pushed back to wait for more doses to be made. A full year later, the new problem with its manufacturing appears to be the presence of impurities in its vaccine. It'll need to solve these production issues if it wants to keep scaling up to serve unmet global demand for doses.</p>\n<p>As with other vaccine stocks, the market hasn't been totally kind to Novavax after these delays.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/03345ce0ccd9cb577b50877da1a14687\" tg-width=\"720\" tg-height=\"387\" width=\"100%\" height=\"auto\"><span>NVAX data by YCharts</span></p>\n<p>And the manufacturing hiccups aren't the only ones. While the company has filed for approval with the World Health Organization, it hasn't yet done so with the Food and Drug Administration (FDA) in the U.S. Originally, that was supposed to happen in mid-2021, but now it might take until mid-2022.</p>\n<p>Though international markets are more likely to be a promising center for growth in comparison to the highly saturated vaccine markets in the U.S., investors can probably expect the stock to get a boost whenever it does end up requesting approval by regulators.</p>\n<h2>The omicron factor</h2>\n<p>As troublesome as getting Novavax's vaccine out the door has been, long-term shareholders have experienced plenty of upside as the pandemic has worn on. In particular, the need for booster shots led the company to start investigating its candidate for suitability as an additional dose. If it is effective as a booster, it'll be yet another opportunity to make more revenue from global sales.</p>\n<p>That'll be especially good for shareholders if the vaccine is found to be effective against the omicron variant, which has so far been a wild card.</p>\n<p>Despite the company's announcement on Dec. 2 that it was pursuing a vaccine specific to the omicron variant, its stock cratered through Dec. 6 due to general panic in the market about the efficacy of the existing vaccines and soon-to-be-released candidates. Then, as the panic eased, Novavax shares surged by more than 28.8% on Dec. 7 after European regulators said that the company's vaccine could be on the brink of approval.</p>\n<p>Good news about its steps toward commercialization will send the stock higher, but new findings about omicron could very easily reverse the situation once again.</p>\n<h2>A high risk moment</h2>\n<p>So for the moment, Novavax is a risky stock for new investors. For those who bought it at one of the many low points of 2021, it's probably worth holding at least a bit longer. There's no telling when the stock will recapture its early-year highs, especially considering the difficulty with manufacturing enough doses to honor its commitments to paying customers.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What in the World Is Going on With Novavax Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat in the World Is Going on With Novavax Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/10/what-in-the-world-is-going-on-with-novavax-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's a cliche to say that certain stocks are like roller coaster rides, but the coronavirus vaccine developer Novavax (NASDAQ:NVAX) has given a completely new meaning to the term over the last 12 ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/10/what-in-the-world-is-going-on-with-novavax-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","NVAX":"诺瓦瓦克斯医药","BK4568":"美国抗疫概念"},"source_url":"https://www.fool.com/investing/2021/12/10/what-in-the-world-is-going-on-with-novavax-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190626076","content_text":"It's a cliche to say that certain stocks are like roller coaster rides, but the coronavirus vaccine developer Novavax (NASDAQ:NVAX) has given a completely new meaning to the term over the last 12 months. While it's up more than 64% this year, in the last three months shareholders have taken losses of about 27%, which means that many of the people who bought shares at the peak early this year are likely to be displeased.\nStill, in the last month alone, Novavax's stock has climbed sharply as the company scored crucial approvals for its vaccine and started commercialization of its vaccine in international markets like the Philippines and Indonesia. And the omicron variant appears to have juiced it even further.\nBut as a result of even more delays with its manufacturing and the filing of a class action lawsuit by shareholders, things are far from settled. Especially for investors who are wondering whether to keep holding Novavax, it's worth investigating what's going on in more detail.\nImage source: Getty Images.\nDelays keep piling up\nIt's obvious that investors are eager for Novavax's vaccine to get the global rollout that the company has been working for since the start of the pandemic, but bumps in the road are slowing things up.\nManufacturing has been a problem since late last year, when the company announced that its all-important phase 3 clinical trials would need to be pushed back to wait for more doses to be made. A full year later, the new problem with its manufacturing appears to be the presence of impurities in its vaccine. It'll need to solve these production issues if it wants to keep scaling up to serve unmet global demand for doses.\nAs with other vaccine stocks, the market hasn't been totally kind to Novavax after these delays.\nNVAX data by YCharts\nAnd the manufacturing hiccups aren't the only ones. While the company has filed for approval with the World Health Organization, it hasn't yet done so with the Food and Drug Administration (FDA) in the U.S. Originally, that was supposed to happen in mid-2021, but now it might take until mid-2022.\nThough international markets are more likely to be a promising center for growth in comparison to the highly saturated vaccine markets in the U.S., investors can probably expect the stock to get a boost whenever it does end up requesting approval by regulators.\nThe omicron factor\nAs troublesome as getting Novavax's vaccine out the door has been, long-term shareholders have experienced plenty of upside as the pandemic has worn on. In particular, the need for booster shots led the company to start investigating its candidate for suitability as an additional dose. If it is effective as a booster, it'll be yet another opportunity to make more revenue from global sales.\nThat'll be especially good for shareholders if the vaccine is found to be effective against the omicron variant, which has so far been a wild card.\nDespite the company's announcement on Dec. 2 that it was pursuing a vaccine specific to the omicron variant, its stock cratered through Dec. 6 due to general panic in the market about the efficacy of the existing vaccines and soon-to-be-released candidates. Then, as the panic eased, Novavax shares surged by more than 28.8% on Dec. 7 after European regulators said that the company's vaccine could be on the brink of approval.\nGood news about its steps toward commercialization will send the stock higher, but new findings about omicron could very easily reverse the situation once again.\nA high risk moment\nSo for the moment, Novavax is a risky stock for new investors. For those who bought it at one of the many low points of 2021, it's probably worth holding at least a bit longer. There's no telling when the stock will recapture its early-year highs, especially considering the difficulty with manufacturing enough doses to honor its commitments to paying customers.","news_type":1},"isVote":1,"tweetType":1,"viewCount":963,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["NVAX","MRNA","PFE"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":90,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/605869638"}